




Instance: composition-en-f5bf35ae4883076cccfcead008b65f47
InstanceOf: CompositionUvEpi
Title: "Composition for heplisav Package Leaflet"
Description:  "Composition for heplisav Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf5bf35ae4883076cccfcead008b65f47)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - heplisav"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What HEPLISAV B is and what it is used for  </li>
<li>What you need to know before you receive  HEPLISAV B  </li>
<li>How HEPLISAV B is given  </li>
<li>Possible side effects  </li>
<li>How to store HEPLISAV B </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What heplisav is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What heplisav is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>HEPLISAV B is a vaccine for use in adults 18 years of age and older to protect against infection with 
the hepatitis B virus. </p>
<p>HEPLISAV B may also protect against hepatitis D which can only occur in people who have hepatitis 
B infection. </p>
<p>What is hepatitis B? </p>
<ul>
<li>
<p>Hepatitis B is an infectious illness of the liver, caused by a virus. Hepatitis B virus infection can 
cause serious liver problems such as  cirrhosis  (scarring in the liver) or liver cancer. </p>
</li>
<li>
<p>Some people infected with the hepatitis B virus become carriers, which means that they may not 
feel ill but continue to have the virus in their body and they can still infect other people. </p>
</li>
<li>
<p>The disease spreads by the hepatitis B virus entering the body through contact with an infected 
person s body fluids, such as in the vagina, blood, semen, or spit (saliva). A mother who is a 
carrier of the virus can also pass the virus to her baby at birth. </p>
</li>
<li>
<p>The main signs of the illness include mild signs of flu (such as headache, fever, and feeling very 
tired), dark urine, pale stools (faeces), yellowing of the skin and eyes (jaundice). However, 
some people with hepatitis B do not look or feel ill. </p>
</li>
</ul>
<p>How HEPLISAV B works </p>
<p>When a person is given the HEPLISAV B vaccine, it helps the body s natural defence system 
(immune system) produce specific protection (antibodies) against the hepatitis B virus.  </p>
<ul>
<li>
<p>HEPLISAV B contains an adjuvant, a substance which improves the body s production of 
antibodies and makes the protection last for longer. </p>
</li>
<li>
<p>A course of two injections of HEPLISAV B is required to provide full protection against 
hepatitis B. </p>
</li>
<li>
<p>HEPLISAV B is not used to treat a person who is already infected with the hepatitis B virus, 
including people infected with the hepatitis B virus and have become carriers for infection.  </p>
</li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take heplisav"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take heplisav"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not receive HEPLISAV B:</p>
<ul>
<li>If you are allergic to any of the components of this vaccine, including yeast (listed in section 6). 
Signs of an allergic reaction may include itchy skin, rash, shortness of breath and swelling of 
the face or tongue. </li>
<li>If you have had a sudden life-threatening, allergic reaction after receiving HEPLISAV B in the 
past. </li>
</ul>
<p>HEPLISAV B should not be given if any of the above apply to you. If you are not sure, talk to your 
doctor, <em>pharmacist</em> or nurse before vaccination with HEPLISAV B. </p>
<p>Warnings and precautions<br />
Talk to your doctor, <em>pharmacist</em> or nurse before receiving HEPLISAV B:</p>
<ul>
<li>If you have any allergies to any of the components of HEPLISAV B (see section 6). </li>
<li>If you have had any health problems after having a vaccine in the past. </li>
<li>Fainting can occur after, or even before, any injection. Therefore tell the doctor, <em>pharmacist</em> 
or nurse if you fainted with a previous injection. </li>
<li>If you are ill with a high fever, your doctor, <em>pharmacist</em> or nurse will delay the vaccination 
until you are feeling better. A minor infection such as a cold should not be a problem, but your 
doctor, <em>pharmacist</em> or nurse will decide if you could still be vaccinated. </li>
</ul>
<p>If you are on dialysis for a kidney problem or if you have a weakened immune system your doctor 
may need to do a blood test to check if the vaccination has worked well enough to protect you against 
hepatitis B. </p>
<p>HEPLISAV B does not protect you against other liver infections such as hepatitis A, C, and E. </p>
<p>As with any vaccine, HEPLISAV B may not protect all people who are vaccinated. </p>
<p>If you are not sure if any of the above apply to you, talk to your doctor, <em>pharmacist</em> or nurse before 
receiving HEPLISAV B. </p>
<p>Children and adolescents 
Since HEPLISAV B has not been tested fully in young people under 18 years of age, it should not be 
used in this age group. </p>
<p>Other medicines and HEPLISAV B 
Tell your doctor, <em>pharmacist</em> or nurse if you are taking, have recently taken or might take any other 
medicines or vaccines. </p>
<p>If HEPLISAV B is given at the same time as an injection of hepatitis B  immuno-globulins , which 
would be given to provide immediate, short-term protection against hepatitis B infection, your doctor, 
<em>pharmacist</em> or nurse will make sure that the two are injected into different parts of the body. </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before receiving this vaccine.  </p>
<p>As a precautionary measure, it is preferable to avoid the use of HEPLISAV B during pregnancy. </p>
<p>It is unknown whether HEPLISAV B is excreted in human milk. A risk to the suckling child cannot be 
excluded. Discuss with your doctor or nurse if you should discontinue breast-feeding or abstain from 
HEPLISAV B vaccination, taking into account the benefit of breast-feeding for your child and the 
benefit of vaccination for you. </p>
<p>Driving and using machines 
You may feel tired or get a headache after receiving HEPLISAV B. If this happens, do not drive or use 
any tools or machines.  </p>
<p>HEPLISAV B contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially  sodium 
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take heplisav"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take heplisav"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The doctor, <em>pharmacist</em> or nurse will give HEPLISAV B as an injection into your muscle, usually in 
your upper arm. </p>
<p>For adults, the course of vaccination is 2 injections:</p>
<ul>
<li>The first injection on a date agreed upon with your doctor or nurse. </li>
<li>The second injection 1 month after the first injection. </li>
</ul>
<p>For adults with a kidney problem including those receiving haemodialysis, the course of vaccination is 
4 injections:</p>
<ul>
<li>The first injection on a date agreed upon with your doctor or nurse. </li>
<li>The second injection 1 month after the first injection. </li>
<li>The third injection 2 months after the first injection </li>
<li>The fourth injection 4 months after the first injection </li>
</ul>
<p>Your doctor will tell you if you need any extra or  booster  injections in the future. 
If you forget a return visit to receive HEPLISAV B 
Talk to your doctor and arrange another visit. </p>
<p>Make sure you complete the injections or you may not be fully protected. Once you have had the first 
injection of HEPLISAV B, the following injection(s) must also be HEPLISAV B (not another type of 
hepatitis B vaccine). </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this vaccine can cause side effects, although not everybody gets them. </p>
<p>Side effects that occurred during clinical trials with HEPLISAV B were as follows: </p>
<p>Serious side effects <br />
Very rare (may affect up to 1 in 10,000 people) 
You should seek immediate treatment if you get any signs of a serious allergic reaction. 
The signs may include: face swelling, low blood pressure, difficulty breathing, loss of consciousness, 
fever, joint stiffness and a skin rash. Such reactions usually start very soon after injection. </p>
<p>Other side effects 
Very Common (may affect more than 1 in 10 people) 
* Headache 
* Muscle aches 
* Feeling tired 
* Pain at the spot where the injection was given 
* Feeling unwell (malaise) </p>
<p>Common (may affect up to 1 in 10 people) 
* Swelling or redness at the spot where the injection was given 
* Fever </p>
<p>Uncommon (may affect up to 1 in 100 people) 
* Feeling sick (nausea) 
* Being sick (vomiting) 
* Diarrhoea 
* Abdominal (belly) pain 
* Allergic reactions (hives, rash and itchiness) 
* Itching at the spot where the injection was given </p>
<p>Rare (may affect up to 1 in 1,000 people) 
* Dizziness 
* Pins and needles </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, <em>pharmacist</em> or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store heplisav"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store heplisav"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this vaccine out of the sight and reach of children. </p>
<p>Do not use this vaccine after the expiry date which is stated on the label and carton after EXP. The 
expiry date refers to the last day of that month. </p>
<p>Store in a refrigerator (2 C - 8 C). Do not freeze. </p>
<p>Keep the pre-filled syringe in the outer carton in order to protect from light. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What HEPLISAV B contains 
One dose (0.5 ml) contains:  </p>
<p>Active substances: </p>
<p>Hepatitis B surface antigen (HBsAg)1,2                           20 micrograms  </p>
<p>1Adjuvanted with 3000 micrograms CpG 1018 adjuvant, a 22-mer immunostimulatory sequence 
oligonucleotide 
2Produced in yeast cells (Hansenula polymorpha) by recombinant DNA technology 
Substance CpG 1018 is included in this vaccine as an adjuvant. Adjuvants are substances included in 
certain vaccines to accelerate, improve and/or prolong the protective effects of the vaccine. </p>
<p>The other ingredients are:<br />
<em> sodium chloride 
* disodium phosphate dodecahydrate <br />
</em> sodium dihydrogen phosphate dihydrate<br />
<em> polysorbate 80 (E 433)<br />
</em> water for injections </p>
<p>What HEPLISAV B looks like and contents of the pack 
HEPLISAV B is a clear to slightly milky, colourless to slightly yellow liquid for injection in pre-filled 
syringe. </p>
<p>HEPLISAV B is available in packs of 1 and 5 pre-filled syringes without needles. </p>
<p>Not all pack sizes may be marketed.  </p>
<p>Marketing Authorisation Holder and Manufacturer 
Dynavax GmbH<br />
Eichsfelder Strasse D-40595 D sseldorf<br />
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien,  ,  esk<br />
republika, Danmark, Eesti,  , Espa a, 
France, Hrvatska, Ireland,  sland, Italia, 
 , Latvija, Lietuva, 
Luxembourg/Luxemburg, Magyarorsz g, 
Malta, Nederland, Norge,  sterreich, Polska, 
Portugal, Rom nia, Slovenija, Slovensk<br />
republika, Suomi/Finland, Sverige, United 
Kingdom (Northern Ireland) 
Dynavax GmbH 
T l/Tel/Te ./Tlf/ /S mi/Puh: 
+49 211 758Deutschland 
Bavarian Nordic A/S 
Tel: +49 89 26200This leaflet was last revised in {MM/YYYY}. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-f5bf35ae4883076cccfcead008b65f47
InstanceOf: CompositionUvEpi
Title: "Composition for heplisav Package Leaflet"
Description:  "Composition for heplisav Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf5bf35ae4883076cccfcead008b65f47)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - heplisav"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du får HEPLISAV B </li>
<li>Sådan får du HEPLISAV B </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What heplisav is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What heplisav is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>HEPLISAV B er en vaccine, der bruges til at beskytte voksne personer fra 18 år og opefter mod 
infektion med hepatitis B-virus. </p>
<p>HEPLISAV B kan også beskytte mod hepatitis D, der kun kan forekomme hos personer, der er smittet 
med hepatitis B. </p>
<p>Hvad er hepatitis B? </p>
<ul>
<li>
<p>Hepatitis B er en smitsom leversygdom, der skyldes et virus. Hepatitis B-virusinfektion kan 
medføre alvorlige leverproblemer som f.eks. cirrose (ardannelse i leveren) eller leverkræft. </p>
</li>
<li>
<p>Nogle mennesker, der er smittet med hepatitis B-virus, bliver bærere, og det betyder, at de ikke 
føler sig syge, men fortsat har virusset i kroppen og derfor fortsat kan smitte andre. </p>
</li>
<li>
<p>Sygdommen spredes ved, at smitten kommer ind i kroppen gennem kontakt med en smittet 
persons kropsvæsker, f.eks. skedesekret, blod, sæd eller spyt. En moder, der er bærer af virusset, 
kan også give det videre til sit barn ved fødslen. </p>
</li>
<li>
<p>De primære tegn på sygdommen er bl.a. milde influenzasymptomer (f.eks. hovedpine, feber og 
voldsom træthed), mørkfarvet urin, bleg afføring, gulfarvning af hud og øjne (gulsot). Det er 
dog ikke alle, der er smittet med hepatitis B, som ser syge ud eller føler sig syge. </p>
</li>
</ul>
<p>Sådan virker HEPLISAV B </p>
<p>Når en person vaccineres med HEPLISAV B, hjælper det kroppens naturlige forsvar (immunsystemet) 
med at danne specifik beskyttelse (antistoffer) mod hepatitis B-virusset. </p>
<ul>
<li>
<p>HEPLISAV B indeholder en adjuvans, dvs. et stof, der forbedrer kroppens dannelse af 
antistoffer, og som bevirker, at beskyttelsen holder længere. </p>
</li>
<li>
<p>For at opnå fuld beskyttelse mod hepatitis B skal man have et vaccinationsforløb med to 
injektioner af HEPLISAV B. </p>
</li>
<li>
<p>HEPLISAV B anvendes ikke til at behandle personer, der allerede er smittet med hepatitis B-
virusset, herunder personer, der er smittet med hepatitis B-virus, og som er blevet bærere af 
infektionen. </p>
</li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take heplisav"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take heplisav"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få HEPLISAV B:</p>
<ul>
<li>hvis du er allergisk over for et eller flere af bestanddelene i denne vaccine, herunder gær (anført 
i pkt. 6). Tegn på en allergisk reaktion er bl.a. hudkløe, udslæt, åndenød og hævet ansigt eller 
tunge. </li>
<li>hvis du tidligere har haft en pludselig livstruende allergisk reaktion efter at have fået 
HEPLISAV B. </li>
</ul>
<p>Du bør ikke få HEPLISAV B, hvis noget af ovenstående gælder for dig. Er du i tvivl, så spørg lægen, 
apotekspersonalet eller sygeplejersken, før du får HEPLISAV B. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du får HEPLISAV B:</p>
<ul>
<li>hvis du har allergi over for en eller flere af bestanddelene i HEPLISAV B (se pkt. 6). </li>
<li>hvis du tidligere har fået et helbredsproblem efter vaccination. </li>
<li>besvimelse kan forekomme efter og endog før en injektion. Fortæl det derfor til lægen, 
apotekspersonalet eller sygeplejersken, hvis du tidligere er besvimet i forbindelse med en 
injektion. </li>
<li>hvis du er syg og har høj feber, for så vil lægen, apotekspersonalet eller sygeplejersken udskyde 
vaccinationen, til du har det bedre. En mindre infektion, f.eks. forkølelse, bør ikke være et 
problem, men lægen, apotekspersonalet eller sygeplejersken vil beslutte, om du stadig kan 
vaccineres. </li>
</ul>
<p>Hvis du er i dialyse pga. et nyreproblem, eller hvis dit immunsystem er svækket, kan lægen være nødt 
til at tage en blodprøve for at tjekke, om vaccinationen har virket godt nok til at beskytte dig mod 
hepatitis B. </p>
<p>HEPLISAV B beskytter dig ikke mod andre leverinfektioner som hepatitis A, C og E. </p>
<p>Som med andre vacciner vil HEPLISAV B muligvis ikke beskytte alle personer, der får vaccinen. 
Hvis du er usikker på, om noget af ovenstående gælder for dig, skal du tale med lægen, 
apotekspersonalet eller sygeplejersken, før du får HEPLISAV B. </p>
<p>Børn og unge 
Da HEPLISAV B ikke er fuldt undersøgt hos unge under 18 år, bør det ikke anvendes i denne 
aldersgruppe. </p>
<p>Brug af anden medicin sammen med HEPLISAV B 
Fortæl det altid til lægen, apotekspersonalet eller sygeplejersken, hvis du tager anden medicin/vaccine, 
for nylig har taget anden medicin/vaccine eller planlægger at tage anden medicin/vaccine. </p>
<p>Hvis HEPLISAV B gives samtidigt med en injektion med hepatitis B-immunglobuliner, som gives for 
at opnå øjeblikkelig, kortvarig beskyttelse mod hepatitis B-infektion, vil lægen, apotekspersonalet eller 
sygeplejersken sørge for, at de to vacciner indsprøjtes forskellige steder på kroppen. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge lægen til råds, før du får denne vaccine. </p>
<p>Det er ukendt, om HEPLISAV B udskilles i human mælk. En risiko for det ammede barn kan ikke 
udelukkes. Tal med lægen eller sygeplejersken om, hvorvidt du bør holde op med at amme eller ikke 
bør vaccineres med HEPLISAV B, idet der skal tages hensyn til fordelene ved amning for dit barn og 
fordelene ved vaccination for dig. </p>
<p>Trafik- og arbejdssikkerhed 
Du kan måske føle dig træt eller få hovedpine efter vaccination med HEPLISAV B. Hvis det sker, må 
du ikke føre motorkøretøj, bruge værktøj eller betjene maskiner. </p>
<p>HEPLISAV B indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take heplisav"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take heplisav"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lægen, apotekspersonalet eller sygeplejersken vil give dig HEPLISAV B som en injektion i en 
muskel, typisk i en overarm. </p>
<p>For voksne består vaccinationsforløbet af 2 injektioner:</p>
<ul>
<li>Den første injektion gives på en dato, som du aftaler med lægen eller sygeplejersken. </li>
<li>Den anden injektion får du 1 måned senere. </li>
</ul>
<p>For voksne med et nyreproblem, inklusive dem, der modtager hæmodialyse, er vaccinationsforløbet 4 
injektioner:</p>
<ul>
<li>Den første indsprøjtning på en dato, som er aftalt med din læge eller sygeplejerske. </li>
<li>Den anden injektion 1 måned efter den første injektion. </li>
<li>Den tredje injektion 2 måneder efter den første injektion </li>
<li>Den fjerde injektion 4 måneder efter den første injektion </li>
</ul>
<p>Din læge vil fortælle dig, om du har brug for ekstra eller "booster"-injektioner i fremtiden. </p>
<p>Hvis du glemmer at komme til den anden vaccination 
Tal med lægen, og aftal et nyt besøg. </p>
<p>Sørg for at få begge injektioner, da du ellers ikke vil være fuldt beskyttet. Når du har fået den første 
injektion af HEPLISAV B, skal de(n) efterfølgende injektion(er) også være med HEPLISAV B (du må 
ikke bruge en anden type hepatitis B-vaccine). </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Denne vaccine kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>De bivirkninger, der blev observeret i kliniske forsøg med HEPLISAV B, er følgende: </p>
<p>Alvorlige bivirkninger 
Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10.000 vaccinerede): 
Du bør søge øjeblikkelig lægehjælp, hvis du får tegn på en alvorlig allergisk reaktion. 
Tegnene er bl.a. hævelse i ansigtet, lavt blodtryk, åndedrætsbesvær, bevidstløshed, feber, ledstivhed 
og hududslæt. Sådanne reaktioner starter typisk hurtigt efter en injektion. </p>
<p>Andre bivirkninger </p>
<p>Meget almindelige bivirkninger (kan forekomme hos mere end 1 ud af 10 vaccinerede) </p>
<ul>
<li>
<p>Hovedpine </p>
</li>
<li>
<p>Muskelsmerter </p>
</li>
<li>
<p>Træthed </p>
</li>
<li>
<p>Smerter ved injektionsstedet </p>
</li>
<li>
<p>Utilpashed </p>
</li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 vaccinerede) </p>
<ul>
<li>
<p>Hævelser eller rødme ved injektionsstedet </p>
</li>
<li>
<p>Feber </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 vaccinerede) </p>
<ul>
<li>
<p>Kvalme </p>
</li>
<li>
<p>Opkastning </p>
</li>
<li>
<p>Diarré </p>
</li>
<li>
<p>Mavesmerter </p>
</li>
<li>
<p>Allergiske reaktioner (nældefeber, udslæt og kløe) </p>
</li>
<li>
<p>Kløe ved injektionsstedet </p>
</li>
</ul>
<p>Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1.000 vaccinerede) </p>
<ul>
<li>
<p>Svimmelhed </p>
</li>
<li>
<p>Stikkende eller brændende fornemmelse. </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store heplisav"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store heplisav"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar vaccinen utilgængeligt for børn. </p>
<p>Brug ikke vaccinen efter den udløbsdato, der står på etiketten og pakningen efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2-8 °C). Må ikke nedfryses. </p>
<p>Opbevar den fyldte sprøjte i den ydre karton for at beskytte mod lys. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>HEPLISAV B indeholder: 
En dosis (0,5 ml) indeholder: </p>
<p>Aktive stoffer: </p>
<p>Hepatitis B-overfladeantigen (HBsAg)1,2                          20 mikrogram </p>
<p>1Adjuveret med 3.000 mikrogram CpG 1018-adjuvans, en 22-mer immunstimulerende oligonukleotid-
sekvens. 
2Dannet i gærceller (Hansenula polymorpha) ved hjælp af rekombinant dna-teknologi 
Stoffet CpG 1018 anvendes som adjuvans i denne vaccine. Adjuvanser er stoffer, der anvendes i 
vacciner til at accelerere, forbedre og/eller forlænge vaccinens beskyttende virkning. </p>
<p>Øvrige indholdsstoffer: </p>
<ul>
<li>
<p>Natriumchlorid </p>
</li>
<li>
<p>Dinatriumphosphatdodecahydrat </p>
</li>
<li>
<p>Natriumdihydrogenphosphatdihydrat </p>
</li>
<li>
<p>Polysorbat 80 (E 433) </p>
</li>
<li>
<p>Vand til injektionsvæsker </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
HEPLISAV B er en klar til let uigennemsigtig, farveløs til gullig injektionsvæske i en fyldt sprøjte. </p>
<p>HEPLISAV B fås i pakker med 1 eller 5 fyldte sprøjter uden kanyle. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Dynavax GmbH 
Eichsfelder Strasse D-40595 Düsseldorf 
Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien, България, Česká 
republika, Danmark, Eesti, Ελλάδα, España, 
France, Hrvatska, Ireland, Ísland, Italia, 
Κύπρος, Latvija, Lietuva, 
Luxembourg/Luxemburg, Magyarország, 
Malta, Nederland, Norge, Österreich, Polska, 
Portugal, România, Slovenija, Slovenská 
republika, Suomi/Finland, Sverige, United 
Kingdom (Northern Ireland) 
Dynavax GmbH 
Tél/Tel/Teл./Tlf/Τηλ/Sími/Puh: 
+49 211 758 
Deutschland 
Bavarian Nordic A/S 
Tel: +49 89 26200 </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}. </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>
<hr />
<p>Nedenstående oplysninger er til sundhedspersoner: </p>
<p>HEPLISAV B: </p>
<ul>
<li>
<p>er en klar til let uigennemsigtig, farveløs til gullig opløsning, som bør være stort set uden 
synlige partikler. Hvis indholdet ikke er som beskrevet, skal sprøjten bortskaffes. </p>
</li>
<li>
<p>bør injiceres intramuskulært i deltoideusområdet på overarmen. </p>
</li>
<li>
<p>bør ikke administreres i glutealområdet (balderne). </p>
</li>
<li>
<p>bør ikke administreres intravenøst, subkutant eller intradermalt. </p>
</li>
<li>
<p>bør ikke gives til personer med overfølsomhed over for det aktive stof eller over for et eller 
flere af hjælpestofferne. </p>
</li>
<li>
<p>bør ikke gives til personer, der har akut, svær febril sygdom. Tilstedeværelse af en mindre 
infektion, f.eks. en forkølelse, er dog ikke en kontraindikation for immunisering. </p>
</li>
<li>
<p>må ikke blandes med andre vacciner i samme sprøjte. </p>
</li>
</ul>
<p>Som med alle injicerbare vacciner bør der være umiddelbar adgang til passende medicinsk behandling 
i tilfælde af sjældne anafylaktiske reaktioner efter administration af HEPLISAV B. </p>
<p>Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-f5bf35ae4883076cccfcead008b65f47
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for heplisav Package Leaflet for language en"
Description: "ePI document Bundle for heplisav Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-f5bf35ae4883076cccfcead008b65f47"
* entry[0].resource = composition-en-f5bf35ae4883076cccfcead008b65f47

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf5bf35ae4883076cccfcead008b65f47"
* entry[=].resource = mpf5bf35ae4883076cccfcead008b65f47
                            
                    
Instance: bundlepackageleaflet-da-f5bf35ae4883076cccfcead008b65f47
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for heplisav Package Leaflet for language da"
Description: "ePI document Bundle for heplisav Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-f5bf35ae4883076cccfcead008b65f47"
* entry[0].resource = composition-da-f5bf35ae4883076cccfcead008b65f47

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf5bf35ae4883076cccfcead008b65f47"
* entry[=].resource = mpf5bf35ae4883076cccfcead008b65f47
                            
                    



Instance: mpf5bf35ae4883076cccfcead008b65f47
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product HEPLISAV B 20 micrograms solution for injection in pre-filled syringe"
Description: "HEPLISAV B 20 micrograms solution for injection in pre-filled syringe"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/20/1503/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "HEPLISAV B 20 micrograms solution for injection in pre-filled syringe"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: f5bf35ae4883076cccfcead008b65f47ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "heplisav"

* status = #current
* mode = #working

* title = "List of all ePIs associated with heplisav"

* subject = Reference(mpf5bf35ae4883076cccfcead008b65f47)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#heplisav "heplisav"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-f5bf35ae4883076cccfcead008b65f47) // heplisav en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-f5bf35ae4883076cccfcead008b65f47) // heplisav da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-f5bf35ae4883076cccfcead008b65f47
InstanceOf: List

* insert f5bf35ae4883076cccfcead008b65f47ListRuleset
    